Keratoconus and Down Syndrome
People with Down Syndrome have a disproportionately higher risk of developing keratoconus than the general population, and many go on to receive corneal cross-linking (CXL)
Mark Hillen
June 28, 2022
People with Down Syndrome have a disproportionately higher risk of developing keratoconus than the general population, and many go on to receive corneal cross-linking (CXL)
Can combining corneal OCT and air puff tonometry help better diagnose the earliest stages of keratoconus? That was the question ELZA researcher, Dr. Nanji Lu,
The Brazilian Association of Cataract and Refractive Surgery (BRASCRS) awarded the ELZA Institute’s Dr. Emilio Torres-Netto the José Ignacio Barraquer Medal, in recognition of his
Dr. Emilio Torres-Netto, MD, PhD, is a cornea and cataract surgeon at the ELZA Institute in Zurich. Emilio was featured in this month’s issue of
Our latest review on “CXL in thin corneas”. It describes all current approaches how to treat thin keratoconus corneas using corneal cross-linking, including our original approach of swelling the cornea and our latest approach, the sub400 protocol.
Photoactivated chromophore for keratitis-corneal cross-linking (PACK-CXL) has progressed a great deal since it was first developed (1) as a treatment for infectious keratitis and corneal
Ophthalmology times asked Farhad Hafezi about what he thinks are the Ophthalmic Challenges in 2022
Dr. Sebastian Siebelman from the media outlet, “Digital Ophthalmology” interviews ELZA AG’s Chief Executive Officer, Nikki Hafezi, as part of their “Visionaries” series. Several topics
Today, a landmark PACK-CXL trial was published that shows that PACK-CXL is an effective corneal infection therapy.
Prof. Hafezi, Medical Director of the ELZA Institute in Dietikon, Zurich, Switzerland, co-authored a recently published paper that indicated that obese adults have a lower